Physician profile
Jayan Nair
NPI 1932280138
$10,552.43
in general payments reported to CMS, 2019-2025
65 companies · $4,998 in 2025
The $4,998 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $122 · 2021: $227 · 2022: $90.60 · 2023: $1,157 · 2024: $3,786 · 2025: $4,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,791 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,791.09 |
| Education | $149.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,059.41 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $647.52 | 2019-2025 | |
| Janssen Biotech, INC. | $624.69 | 2023-2025 | Tecvayli, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $542.78 | 2023-2025 | |
| Daiichi Sankyo INC. | $537.58 | 2023-2025 | Enhertu, Datroway |
| Celgene Corporation | $497.28 | 2023-2025 | Reblozyl, Opdualag, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $438.35 | 2024-2025 | Fruzaqla, Hyqvia, Ninlaro |
| Glaxosmithkline, LLC. | $376.43 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Incyte Corporation | $375.37 | 2023-2025 | Monjuvi, Jakafi, Niktimvo |
| Astrazeneca Pharmaceuticals LP | $355.63 | 2020-2025 | Enhertu, Calquence, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $344.89 | 2019-2025 | Opdivo |
| Gilead Sciences, INC. | $340.69 | 2024-2025 | Trodelvy |
| Abbvie INC. | $241.91 | 2024-2025 | |
| Genzyme Corporation | $187.27 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $183.41 | 2024-2025 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $178.33 | 2023-2024 | Brukinsa |
| Eisai INC. | $176.38 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $172.64 | 2024-2025 | Libtayo, Lynozyfic |
| Beone Medicines USA, INC. | $159.14 | 2025 | Brukinsa, Tevimbra |
| Array Biopharma INC | $153.06 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Astellas Pharma US INC | $151.97 | 2023-2025 | Padcev, Xospata, Vyloy |
| Lilly USA, LLC | $149.76 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Kite Pharma, INC. | $148.36 | 2023-2025 | Yescarta |
| Syndax Pharmaceuticals, INC. | $145.62 | 2025 | Revuforj |
| Sobi, INC | $135.85 | 2024-2025 | |
| Taiho Oncology, INC. | $135.23 | 2024-2025 | |
| Intuitive Surgical, INC. | $134.62 | 2025 | |
| Seagen INC. | $132.23 | 2023-2025 | Padcev, Adcetris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.42 | 2019-2025 | Gilotrif |
| Galvanize Therapeutics, INC | $123.55 | 2024 | Aliya System |
| Boston Scientific Corporation | $102.95 | 2021 | |
| Emd Serono, INC. | $99.97 | 2023-2025 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $98.14 | 2025 | Onivyde |
| Amgen INC. | $79.49 | 2019 | |
| Stemline Therapeutics INC. | $77.37 | 2020-2025 | Orserdu |
| Exelixis INC. | $77.33 | 2024-2025 | Cabometyx |
| Sumitomo Pharma America, INC. | $76.78 | 2023-2025 | Orgovyx |
| Medical Device Business Services, INC. | $76.76 | 2020 | |
| Aveo Pharmaceuticals, INC. | $70.05 | 2023-2024 | Fotivda |
| Iovance Biotherapeutics, INC. | $68.00 | 2025 | Amtagvi |
| Genentech USA, INC. | $61.61 | 2019-2024 | Tecentriq, Gavreto, Alecensa |
| Pharmaessentia USA Corporation | $55.81 | 2024-2025 | Besremi |
| Puma Biotechnology, INC. | $55.65 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $53.64 | 2024 | Xpovio |
| Genentech, INC. | $53.45 | 2025 | Tecentriq |
| Tersera Therapeutics LLC | $52.95 | 2024-2025 | Zoladex, Xermelo |
| Geron Corporation | $44.71 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $35.86 | 2023-2024 | Cosela, Monoferric |
| Deciphera Pharmaceuticals INC. | $35.08 | 2024-2025 | Qinlock, Tgct, Romvimza |
| Alexion Pharmaceuticals, INC. | $32.39 | 2024 | Ultomiris |
| Immunocore Limited | $30.26 | 2025 | Kimmtrak |
| Recordati_rare_diseases_inc. | $25.40 | 2025 | Enjaymo |
| Dendreon Pharmaceuticals LLC | $24.81 | 2024 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $23.73 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $20.76 | 2023 | Imbruvica |
| Genmab U.S., INC. | $19.37 | 2025 | Epkinly |
| Morphosys, US INC. | $19.33 | 2023 | Monjuvi |
| G1 Therapeutics, INC. | $15.98 | 2022 | |
| Fennec Pharmaceuticals, INC. | $15.64 | 2025 | Fyarro |
| Janssen Pharmaceuticals, INC | $14.89 | 2019 | |
| Kyowa Kirin, INC. | $14.40 | 2024 | Poteligeo |
| Adc Therapeutics America, INC. | $13.49 | 2024 | |
| Agios Pharmaceuticals, INC. | $13.18 | 2023 | Pyrukynd |
| Emmaus Medical, INC. | $6.99 | 2023 | Endari |
| Pharmaand Gmbh | $6.84 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayan Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.